Scholarlink

<p>The COVID-19 pandemic, caused by the continuously evolving SARS-CoV-2 virus, has presented persistent global health challenges. As novel variants emerge, many with enhanced transmissibility and immune evasion capabilities, concerns have intensified regarding the efficacy of existing vaccines and therapeutics. This review provides a comprehensive overview of the current landscape of COVID-19 vaccination, including the development and performance of monovalent and bivalent boosters, and examines their effectiveness against newly emerging variants of interest (VOIs) and variants under monitoring (VUMs), such as JN.1, KP.2, and XEC. We also explore real-world vaccine effectiveness, antibody neutralization studies, and the latest updates from WHO advisory groups. Beyond vaccines, we discuss evolving treatment approaches, including the use of monoclonal antibodies (mAbs), small-molecule antivirals, and host-targeted therapies. As resistance to antiviral agents and mAbs continues to emerge, combination therapies and next-generation broadly neutralizing antibodies offer promising avenues. This review underscores the importance of ongoing surveillance, rapid vaccine reformulation, and the development of adaptive treatment strategies to mitigate the impact of emerging SARS-CoV-2 variants and protect vulnerable populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Emerging SARS-CoV-2 variants: genomic shifts, immune evasion, and therapeutic perspectives

  • 期刊论文

  • 发表日期：

    2025年9月10日

查看全文
  • Racha Wehbe,
  • Nour Khoshman,
  • Zahraa Ousseily,
  • Sarah Ayad Al-Tameemi,
  • Rania El Majzoub,
  • Mehdi Najar,
  • Makram Merimi,
  • Hussein Fayyad-Kazan,
  • Bassam Badran,
  • Mohammad Fayyad-Kazan

摘要

The COVID-19 pandemic, caused by the continuously evolving SARS-CoV-2 virus, has presented persistent global health challenges. As novel variants emerge, many with enhanced transmissibility and immune evasion capabilities, concerns have intensified regarding the efficacy of existing vaccines and therapeutics. This review provides a comprehensive overview of the current landscape of COVID-19 vaccination, including the development and performance of monovalent and bivalent boosters, and examines their effectiveness against newly emerging variants of interest (VOIs) and variants under monitoring (VUMs), such as JN.1, KP.2, and XEC. We also explore real-world vaccine effectiveness, antibody neutralization studies, and the latest updates from WHO advisory groups. Beyond vaccines, we discuss evolving treatment approaches, including the use of monoclonal antibodies (mAbs), small-molecule antivirals, and host-targeted therapies. As resistance to antiviral agents and mAbs continues to emerge, combination therapies and next-generation broadly neutralizing antibodies offer promising avenues. This review underscores the importance of ongoing surveillance, rapid vaccine reformulation, and the development of adaptive treatment strategies to mitigate the impact of emerging SARS-CoV-2 variants and protect vulnerable populations.